中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(4): 973-976

Mechanism of action of suppressor of cytokine signaling 1 in the development and progression of liver inflammatory diseases

DOI: 10.3969/j.issn.1001-5256.2021.04.055

  • Department of Hepatobiliary Diseases, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China

  • Received Date: 2020-09-19
  • Accepted Date: 2020-10-10
  • Published Date: 2021-04-20
    Abstract
  • The development of liver inflammatory diseases is associated with autoimmunity and inflammatory response. As a negative feedback regulator of cell signal, suppressor of cytokine signaling 1 (SOCS1) plays a key role in the development and progression of inflammatory diseases. This article mainly introduces the mechanism of action of SOCS1 in autoimmunity and inflammatory response and briefly describes its role in the development and progression of liver inflammatory diseases such as viral hepatitis and nonalcoholic steatohepatitis. The analysis shows that the abnormal expression of SOCS1 in inflammatory response is associated with the regulation of cytokine receptor, Toll-like receptor, and hormone receptor signal, which leads to the development of inflammatory diseases. Therefore, SOCS1 has potential prospects as an auxiliary means for the diagnosis and treatment of liver inflammatory diseases.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    World Health Organization. Global hepatitis report, 2017[R/OL]. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
    [2]
    ZHANG S, WANG F, ZHANG Z. Current advances in the elimination of hepatitis B in China by 2030[J]. Front Med, 2017, 11(4): 490-501. DOI: 10.1007/s11684-017-0598-4.
    [3]
    GAO Y, YANG J, SUN F, et al. Prevalence of anti-HCV antibody among the general population in mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(3): ofz040. DOI: 10.1093/ofid/ofz040.
    [4]
    FAN JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28 Suppl 1: 11-17. DOI: 10.1111/jgh.12036.
    [5]
    STARR R, WILLSON TA, VINEY EM, et al. A family of cytokine-inducible inhibitors of signalling[J]. Nature, 1997, 387(6636): 917-921. DOI: 10.1038/43206.
    [6]
    ENDO TA, MASUHARA M, YOKOUCHI M, et al. A new protein containing an SH2 domain that inhibits JAK kinases[J]. Nature, 1997, 387(6636): 921-924. DOI: 10.1038/43213.
    [7]
    GISSELBRECHT S. The CIS/SOCS proteins: A family of cytokine-inducible regulators of signaling[J]. Eur Cytokine Netw, 1999, 10(4): 463-470. http://www.ncbi.nlm.nih.gov/pubmed/10586112
    [8]
    CHANDRAKAR P, PARMAR N, DESCOTEAUX A, et al. Differential induction of SOCS isoforms by leishmania donovani impairs macrophage-T cell cross-talk and host defense[J]. J Immunol, 2020, 204(3): 596-610. DOI: 10.4049/jimmunol.1900412.
    [9]
    AHMED CM, LARKIN J 3rd, JOHNSON HM. SOCS1 mimetics and antagonists: A complementary approach to positive and negative regulation of immune function[J]. Front Immunol, 2015, 6: 183. DOI: 10.3389/fimmu.2015.00183.
    [10]
    DURHAM GA, WILLIAMS J, NASIM MT, et al. Targeting SOCS proteins to control JAK-STAT signalling in disease[J]. Trends Pharmacol Sci, 2019, 40(5): 298-308. DOI: 10.1016/j.tips.2019.03.001.
    [11]
    BAETZ A, KOELSCHE C, STREBOVSKY J, et al. Identification of a nuclear localization signal in suppressor of cytokine signaling 1[J]. FASEB J, 2008, 22(12): 4296-4305. DOI: 10.1096/fj.08-116079.
    [12]
    ZHANG JG, FARLEY A, NICHOLSON SE, et al. Correction for Zhang et al., The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation[J]. Proc Natl Acad Sci U S A, 2015, 112(22): e2979. DOI: 10.1073/pnas.1507812112.
    [13]
    YEGANEH M, GUI Y, KANDHI R, et al. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver[J]. Oncogene, 2016, 35(32): 4200-4211. DOI: 10.1038/onc.2015.485.
    [14]
    STARR R, WILLSON TA, VINEY EM, et al. A family of cytokine-inducible inhibitors of signalling[J]. Nature, 1997, 387(6636): 917-921. DOI: 10.1038/43206.
    [15]
    YING J, QIU X, LU Y, et al. SOCS1 and its potential clinical role in tumor[J]. Pathol Oncol Res, 2019, 25(4): 1295-1301. DOI: 10.1007/s12253-019-00612-5.
    [16]
    LIAU N, LAKTYUSHIN A, LUCET IS, et al. The molecular basis of JAK/STAT inhibition by SOCS1[J]. Nat Commun, 2018, 9(1): 1558. DOI: 10.1038/s41467-018-04013-1.
    [17]
    SUN R, PARK O, HORIGUCHI N, et al. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice[J]. Hepatology, 2006, 44(4): 955-966. DOI: 10.1002/hep.21344.
    [18]
    ILANGUMARAN S, BOBBALA D, RAMANATHAN S. SOCS1: Regulator of T cells in autoimmunity and cancer[J]. Curr Top Microbiol Immunol, 2017, 410: 159-189. DOI: 10.1007/82_2017_63.
    [19]
    ZHAO ZX, CAI QX, PENG XM, et al. Expression of SOCS-1 in the liver tissues of chronic hepatitis B and its clinical significance[J]. World J Gastroenterol, 2008, 14(4): 607-611. DOI: 10.3748/wjg.14.607.
    [20]
    WAHID B, RAFIQUE S, SALEEM K, et al. An increase in expression of SOCS1 gene with increase in hepatitis C virus viral load[J]. J Interferon Cytokine Res, 2018, 38(3): 122-128. DOI: 10.1089/jir.2017.0129.
    [21]
    USHIKI T, HUNTINGTON ND, GLASER SP, et al. Rapid inflammation in mice lacking both SOCS1 and SOCS3 in hematopoietic cells[J]. PLoS One, 2016, 11(9): e0162111. DOI: 10.1371/journal.pone.0162111.
    [22]
    SINGH P, DASS J FP. A biomolecular network driven proteinic interaction in HCV clearance[J]. Cell Biochem Biophys, 2018, 76(1-2): 161-172. DOI: 10.1007/s12013-017-0837-y.
    [23]
    WAHID B. Role of SOCS1 gene in chronic hepatitis C virus patients: A mini-review[J]. J Interferon Cytokine Res, 2020, 40(9): 454-459. DOI: 10.1089/jir.2018.0109.
    [24]
    WANG W, BIAN H, LI F, et al. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines[J]. Cell Mol Life Sci, 2018, 75(14): 2627-2641. DOI: 10.1007/s00018-018-2753-8.
    [25]
    LEBOSSÉ F, TESTONI B, FRESQUET J, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B[J]. J Hepatol, 2017, 66(5): 897-909. DOI: 10.1016/j.jhep.2016.12.024.
    [26]
    TANG Y, CHEN X, ZHANG Y, et al. Fusion protein of tapasin and hepatitis B core antigen 18-27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice[J]. Mol Med Rep, 2014, 9(4): 1171-1178. DOI: 10.3892/mmr.2014.1947.
    [27]
    XU Y, HU Y, SHI B, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells[J]. Mol Immunol, 2009, 46(13): 2640-2646. DOI: 10.1016/j.molimm.2009.04.031.
    [28]
    YOUSSEF SS, HAMDY NM. SOCS1 and pattern recognition receptors: TLR9 and RIG-I; novel haplotype associations in Egyptian fibrotic/cirrhotic patients with HCV genotype 4[J]. Arch Virol, 2017, 162(11): 3347-3354. DOI: 10.1007/s00705-017-3498-7.
    [29]
    ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: Clinical impact[J]. J Hepatol, 2018, 68(2): 268-279. DOI: 10.1016/j.jhep.2017.09.003.
    [30]
    KEMPINSKA-PODHORODECKA A, WUNSCH E, MILKIEWICZ P, et al. The association between SOCS1-1656G > A polymorphism, insulin resistance and obesity in nonalcoholic fatty liver disease (NAFLD) patients[J]. J Clin Med, 2019, 8(11): 1912. DOI: 10.3390/jcm8111912.
    [31]
    YANG G, BADEANLOU L, BIELAWSKI J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome[J]. Am J Physiol Endocrinol Metab, 2009, 297(1): e211-e224. DOI: 10.1152/ajpendo.91014.2008.
    [32]
    SUN Q, XIANG RL, YANG YL, et al. Suppressor of cytokine signaling 1 protects rat pancreatic islets from cytokine-induced apoptosis through Janus kinase/signal transducers and activators of transcription pathway[J]. Chin Med J (Engl), 2013, 126(21): 4048-4053. http://www.ncbi.nlm.nih.gov/pubmed/24229672
    [33]
    LIANG YB, TANG H, CHEN ZB, et al. Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type[J]. Mol Med Rep, 2017, 16(5): 6405-6411. DOI: 10.3892/mmr.2017.7384.
    [34]
    NORKINA O, DOLGANIUC A, CATALANO D, et al. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes[J]. Alcohol Clin Exp Res, 2008, 32(9): 1565-1573. DOI: 10.1111/j.1530-0277.2008.00726.x.
    [35]
    TAN L, JIANG W, LU A, et al. miR-155 aggravates liver ischemia/reperfusion injury by suppressing SOCS1 in mice[J]. Transplant Proc, 2018, 50(10): 3831-3839. DOI: 10.1016/j.transproceed.2018.08.060.
    [36]
    YUAN FH, CHEN YL, ZHAO Y, et al. microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS-1 in rats with sepsis[J]. J Cell Physiol, 2019, 234(10): 17839-17853. DOI: 10.1002/jcp.28410.
    [37]
    KEMPINSKA-PODHORODECKA A, MILKIEWICZ M, WASIK U, et al. Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 pathway[J]. Int J Mol Sci, 2017, 18(2): 289. DOI: 10.3390/ijms18020289.
    [38]
    CHEN YS, LIU HM, LEE TY. Ursodeoxycholic acid regulates hepatic energy homeostasis and white adipose tissue macrophages polarization in leptin-deficiency obese mice[J]. Cells, 2019, 8(3): 253. DOI: 10.3390/cells8030253.
    [39]
    CHANG E, KIM DH, YANG H, et al. CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes[J]. PLoS One, 2018, 13(10): e0206152. DOI: 10.1371/journal.pone.0206152.
    [40]
    WANG X, SUN L, ZHANG L, et al. Effect of adoptive transfer or depletion of regulatory T cells on triptolide-induced liver injury[J]. Front Pharmacol, 2016, 7: 99. DOI: 10.3389/fphar.2016.00099.
    [41]
    DU P, MA Q, ZHU ZD, et al. Mechanism of corilagin interference with IL-13/STAT6 signaling pathways in hepatic alternative activation macrophages in schistosomiasis-induced liver fibrosis in mouse model[J]. Eur J Pharmacol, 2016, 793: 119-126. DOI: 10.1016/j.ejphar.2016.11.018.
    [42]
    LI SS, YANG M, CHEN YP, et al. Dendritic cells with increased expression of suppressor of cytokine signaling 1(SOCS1) gene ameliorate lipopolysaccharide/d-galactosamine-induced acute liver failure[J]. Mol Immunol, 2018, 101: 10-18. DOI: 10.1016/j.molimm.2018.05.016.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (414) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return